Star Lake Bioscience Co., Inc. Zhaoqing Guangdong (600866.SS) manufactures and markets biochemical pharmaceuticals, food additives, and feed additives utilizing biological fermentation and biochemical engineering technologies; core products include pharmaceutical intermediates and APIs such as inosine, ribavirin, L-proline, guanosine, adenosine, adenine, adefovir dipivoxil tablets, memantine hydrochloride, arginine, and D-ribose under the Yue Bao brand; food additives encompassing disodium 5'-ribonucleotide (I+G), disodium 5'-inosinate (IMP), disodium 5'-guanylate (GMP), and fructose syrups (F55, F42, F60) under the Star Lake brand; and feed additives like L-valine, L-threonine, and L-lysine under the Star Lake brand. The company, founded in 1964 as Zhaoqing Agricultural Microorganism Factory and listed on the Shanghai Stock Exchange in 1994, maintains headquarters in Zhaoqing, Guangdong province, China, with primary operations in China and international markets serving pharmaceutical firms, food processors, and animal feed producers. Recent developments encompass the completion of its acquisition of a 99.22% stake in Ningxia EPPEN Biotech Co., Ltd. in November 2022 for approximately CNY 5.376 billion to bolster biotechnology capabilities; plans in 2025 to issue over 146 million shares for fundraising; investment of up to CNY 3.30 billion in a new amino acid production facility; a 65.2% net profit increase in the first half of 2025 amid revenue of CNY 8.16 billion; and a 39.12% rise in 2024 net profits with an 88.55% surge in Q1 2025 earnings.